Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

The future of immunisation policy, implementation, and financing.
Levine, OS; Bloom, DE; Cherian, T; De Quadros, C; Sow, S; Wecker, J; Duclos, P; GREENWOOD, B;
2011
Lancet, (2011).378 9789 10.1016/S0140-6736(11)60406-6.
Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi.
Fowlkes, A; Witte, D; Beeler, J; Audet, S; Garcia, P; Curns, A; Yang, C; Fudzulani, R; Broadhead, R; Bellini, WJ; CUTTS, F; Helfand, RF;
2011
The Journal of infectious diseases, (2011).204 Su suppl_ 10.1093/infdis/jir135.
Impact of early life exposures to geohelminth infections on the development of vaccine immunity, allergic sensitization, and allergic inflammatory diseases in children living in tropical Ecuador: the ECUAVIDA birth cohort study.
Cooper, PJ; Chico, ME; Guadalupe, I; Sandoval, CA; Mitre, E; Platts-Mills, TA E; Barreto, ML; RODRIGUES, LC; Strachan, DP; Griffin, GE;
2011
BMC infectious diseases, (2011).11 1 10.1186/1471-2334-11-184.
Comparative economic evaluation of Haemophilus influenzae type b vaccination in Belarus and Uzbekistan.
GRIFFITHS, UK; CLARK, A; Shimanovich, V; Glinskaya, I; Tursunova, D; Kim, L; Mosina, L; Hajjeh, R; EDMOND, K;
2011
PloS one, (2011).6 6 10.1371/journal.pone.0021472.
Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.
Russell, FM; Balloch, A; Licciardi, PV; Carapetis, JR; Tikoduadua, L; Waqatakirewa, L; Cheung, YB; MULHOLLAND, EK; Tang, ML K;
2011
Vaccine, (2011).29 27 10.1016/j.vaccine.2011.04.038.
Scope for rotavirus vaccination in India: revisiting the scientific evidence.
Neogi, SB; Hasan, H; SHEIKH, K; Zodpey, S;
2011
Indian journal of pediatrics, (2011).78 10 10.1007/s12098-011-0448-3.
Another step down the development pipeline for the novel tuberculosis vaccine MVA-85A.
DOCKRELL, HM;
2011
The Journal of infectious diseases, (2011).203 12 10.1093/infdis/jir200.
Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales.
FLASCHE, S; Slack, M; MILLER, E;
2011
Euro surveillance, (2011).16 20 10.2807/ese.16.20.19868-en.
Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales.
FLASCHE, S; Slack, M; Miller, E;
2011
EUROSURVEILLANCE, (2011).16 20(20), Art.No. ARTN 19868, 13-18.
Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.
JIT, M; Demarteau, N; Elbasha, E; Ginsberg, G; Kim, J; Praditsitthikorn, N; Sinanovic, E; Hutubessy, R;
2011
BMC medicine, (2011).9 1 10.1186/1741-7015-9-54.